

Corrected Change of Director's Interest Notice - Pasquale Rombola

Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company") refers to the Appendix 3Y – 'Change of Director's Interest Notice - Pasquale Rombola' lodged with the ASX on Friday, 15 August 2025.

The Company advises that the original Appendix 3Y contained an error in the expiry date of the options issued. The previous announcement incorrectly stated:

- **370,000 Ordinary Shares & 50,000 Options** exercisable at \$0.14 expiring on **29 April 2025** for Rombola Superannuation Pty Ltd <Rombola Super Fund A/C>

The correct details are:

- **370,000 Ordinary Shares & 50,000 Options** exercisable at \$0.14 expiring on **13 August 2027** for Rombola Superannuation Pty Ltd <Rombola Super Fund A/C>.

An updated Appendix 3Y reflecting the correct expiry date is attached.

The Company apologises for any inconvenience caused.

This announcement has been authorised for release by the Company Secretary.

For further information, please contact:

Dr Luke Reid
Chief Executive Officer
luke.reid@microba.com

Investor / Media Relations
investor@microba.com
<https://ir.microba.com/welcome>

About Microba Life Sciences Limited

Microba Life Sciences is a company at the forefront of microbiome diagnostics & therapeutics and are on a mission to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions. For more information visit www.microba.com



JOIN MICROBA'S INTERACTIVE INVESTOR HUB

For more Company information and to engage with management by asking questions about Microba's latest announcements and updates, visit ir.microba.com/welcome

Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: Microba Life Sciences Ltd
ABN: 82 617 096 652

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Pasquale Rombola
Date of last notice	20 November 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	1. Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	<ol style="list-style-type: none">Rombola Family Pty Ltd <Rombola Family A/C>. Pasquale Rombola is the sole director and sole shareholder of Rombola Family Pty Ltd and a beneficiary of the Rombola Family TrustRombola Superannuation Pty Ltd <Rombola Super Fund A/C>. Pasquale Rombola is a director and a shareholder of Rombola Superannuation Pty Ltd and a beneficiary of the Rombola Super Fund.
Date of change	13 August 2025
No. of securities held prior to change	<ol style="list-style-type: none">5,700,000 Ordinary Shares270,000 Ordinary Shares

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Class	Ordinary Shares & Options
Number acquired	600,000 Ordinary Shares and 300,000 Options with an exercise price of \$0.14, expiring on 13 August 2027.
Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$54,000
No. of securities held after change	<ol style="list-style-type: none"> 1. 6,200,000 Ordinary Shares & 250,000 Options with an exercise price of \$0.14, expiring on 13 August 2027. 2. 370,000 Ordinary Shares & 50,000 Options exercisable at \$0.14, expiring 13 August 2027.
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Participation in Microba Placement announced to the ASX on 23 June 2025

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – +Closed period

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

For personal use only

+ See chapter 19 for defined terms.